Citations

Clear

116 citation(s) found for "Davis, Mark".

Pediatric Hospital Dermatology: Experience with Inpatient and Consult Services at the Mayo Clinic
Storan, Eoin R. , McEvoy, Marian T., Wetter, David A. , el‐Azhary, Rokea A. , Hand, Jennifer L. , Bridges, Alina G. , Camilleri, Michael , Davis, Mark D. P. , Davis, Dawn Marie R. , El-Azhary, Rokea

Mayo Clinic

Pediatric Dermatology | February 14, 2013 | Volume: 30 | Issue: 4 | Pages: 433-437

10.1111/pde.12081 | PMID 23406424 Get It

AbstractData describing the management of pediatric patients admitted to a hospital under the care of a dermatologist and dermatology hospital consults for pediatric inpatients are limited. We aim to describe the role of an inpatient hospital service jointly run by dermatology and pediatrics and the activities of a pediatric dermatology hospital consult service. We retrospectively identified pediatric (age < 18 yrs) dermatology inpatients and hospital consult patients from January 1, 2009, through December 31, 2010. We examined patient demographics, indications for admission, length of stay, treatment provided, consult‐requesting service, and consult diagnosis. One hundred eight admissions were by a dermatologist. The mean age was 5.8 years; the median length of stay was 3 days. Indications for admission included atopic dermatitis (86.1%), psoriasis (3.7%), and eczema herpeticum (2.8%). The main treatment provided was wet dressings (97.2%). Eighty‐three dermatology hospital consults were requested. The mean age was 7.4 years. The main indications for dermatology consultation included drug rash (12.1%), cutaneous infections (12.1%), contact dermatitis (9.6%), psoriasis (8.4%), atopic dermatitis (6.0%), and hemangiomas (6.0%). This study describes the utility of the hospital pediatric dermatology inpatient and consult services in treating patients with severe skin disease.
Update of management of connective tissue diseases: livedoid vasculopathy
Gonzalez‐Santiago, Tania M., Davis, Mark D. P.

Mayo Clinic

Dermatologic Therapy | June 14, 2012 | Volume: 25 | Issue: 2 | Pages: 183-194

10.1111/j.1529-8019.2012.01490.x | PMID 22741937 Get It

Outcomes After Coronary Stent Implantation in Patients With Metal Allergy
Romero‐Brufau, Santiago , Best, Patricia J.M. , Holmes, David R. , Mathew, Verghese, Davis, Mark D.P. , Sandhu, Gurpreet S. , Lennon, Ryan J. , Rihal, Charanjit S. , Gulati, Rajiv , Rihal, Charanjit S. , Romero-Brufau, Santiago

Mayo Clinic

Circulation: Cardiovascular Interventions | March 29, 2012 | Volume: 5 | Issue: 2 | Pages: 220-226

10.1161/circinterventions.111.966614 | PMID 22456027 Get It

Background— Clinical outcomes after stent placement in patients with a history of metal allergy remain incompletely understood. We performed a single-center retrospective study to evaluate such outcomes. Methods and Results— Twenty-nine allergic patients who underwent coronary stent implantation were compared with a nonallergic group (n=250) matched for demographics and a propensity score for allergy to metal. Hypersensitivity to nickel was reported in 26 of 29 and chromium in 9 of 29. Patch testing performed in 11 of 29 patients was positive in all. Comparing allergy versus control subjects, there were no differences in number of segments treated (1.4±0.7 versus 1.5±0.7), stents placed (1.7±1.1 versus 1.6±0.9), and frequency of drug-eluting stent usage (52% versus 60%). In-hospital death (0% versus 0%), myocardial infarction (MI, 4% versus 3%, P =0.27), and 30-day death (3% versus 0%, P =0.53) and MI (3% versus 4%, P =0.71) were statistically similar. There were no differences in 4-year death (12% versus 13%), target lesion revascularization (TLR, 13 versus 17%, P =0.54), or death/MI/TLR (24% versus 34%, P =0.20). Clinically driven repeat angiography in 12 of 29 allergy patients revealed binary restenosis rates of 27% in bare metal stents and 0% in drug-eluting stents, with mean diameter in-stent restenosis of 36% and 8%, respectively. There was no change in circulating eosinophil and lymphocyte counts after stenting in the allergy group (0.19–0.20, P =0.67, and 1.90–1.79, P =0.59, respectively). Conclusions— A history of metal allergy was not associated with adverse early or late outcomes in this single-center study.
Severe case and literature review of primary erythromelalgia: Novel SCN9A gene mutation
Rooke, Thom W. , Davis, Mark D.P. , Kalsi, Henna, Kurth, Ingo , Richardson, Randal , Skeik, Nedaa , Davis, Dawn Marie R.

Mayo Clinic

Vascular Medicine | October 27, 2011 | Volume: 17 | Issue: 1 | Pages: 44-49

10.1177/1358863x11422584 | PMID 22033523 Get It

Erythromelalgia is a rare clinical syndrome characterized by intermittent heat, redness, swelling and pain more commonly affecting the lower extremities. Symptoms are mostly aggravated by warmth and are eased by a cold temperature. In some cases, symptoms can be very severe and disabling. Erythromelalgia can be classified as either familial or sporadic, with the familial form inherited in an autosomal dominant manner. Recently, there has been a lot of progress in studying Na(v)1.7 sodium channels (expressed mostly in the sympathetic and nociceptive small-diameter sensory neurons of the dorsal root ganglion) and different mutations affecting the encoding SCN9A gene that leads to channelopathies responsible for some disorders, including primary erythromelalgia. We present a severe case of progressive primary erythromelalgia caused by a new de novo heterozygous missense mutation (c.2623C>G) of the SCN9A gene which substitutes glutamine 875 by glutamic acid (p.Q875E). To our knowledge, this mutation has not been previously reported in the literature. We also provided a short literature review about erythromelalgia and Na(v) sodium channelopathies.
Eosinophil Ribonucleases and Their Cutaneous Lesion-Forming Activity
Plager, Douglas A., Davis, Mark D.P. , Andrews, Amy G., Coenen, Michael J., George, Terry J., Gleich, Gerald J. , Leiferman, Kristin M.

Mayo Clinic

The Journal of Immunology | August 28, 2009 | Volume: 183 | Issue: 6 | Pages: 4013-4020

10.4049/jimmunol.0900055 | PMID 19717523 Get It

Abstract Eosinophil granule proteins are deposited in cutaneous lesions in many human diseases, but how these proteins contribute to pathophysiology is obscure. We injected eosinophil cationic protein (ECP or RNase 3), eosinophil-derived neurotoxin (EDN or RNase 2), eosinophil peroxidase (EPO), and major basic protein-1 (MBP1) intradermally into guinea pig and rabbit skin. ECP and EDN each induced distinct skin lesions at ≥2.5 μM that began at 2 days, peaking at ∼7 days and persisting up to 6 wk. These lesions were ulcerated (ECP) or crusted (EDN) with marked cellular infiltration. EPO and MBP1 (10 μM) each produced perceptible induration and erythema with moderate cellular infiltration resolving within 2 wk. ECP and EDN localized to dermal cells within 2 days, whereas EPO and MBP1 remained extracellular. Overall, cellular localization and RNase activity of ECP and EDN were critical for lesion formation; differential glycosylation, net cationic charge, or RNase activity alone did not account for lesion formation. Ulcerated lesions from patients with the hypereosinophilic syndrome showed ECP and EDN deposition comparable to that in guinea pig skin. In conclusion, ECP and EDN disrupt skin integrity and cause inflammation. Their presence in ulcerative skin lesions may explain certain findings in human eosinophil-associated diseases.
Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
Yee, Cassian , Thompson, John A. , Roche, Patrick C. , Byrd, David R. , Lee, Peter P. , Piepkorn, Michael W., Kenyon, Karla, Riddell, Stanley R. , Davis, Mark M. , Greenberg, Philip D.

Mayo Clinic

The Journal of Experimental Medicine | July 26, 2002 | Volume: 192 | Issue: 11 | Pages: 1637-1644

10.1084/jem.192.11.1637 | PMID 11104805 Get It

Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting of tumor antigens representing normal proteins can result in autoimmune toxicity has been postulated but never demonstrated previously in humans. In this study, we describe a patient with metastatic melanoma who developed inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1–specific CD8+ T cell clones. Analysis of the infiltrating lymphocytes in skin and tumor biopsies using T cell–specific peptide–major histocompatibility complex tetramers demonstrated a localized predominance of MART-1–specific CD8+ T cells (&gt;28% of all CD8 T cells) that was identical to the infused clones (as confirmed by sequencing of the complementarity-determining region 3). In contrast to skin biopsies obtained from the patient before T cell infusion, postinfusion biopsies demonstrated loss of MART-1 expression, evidence of melanocyte damage, and the complete absence of melanocytes in affected regions of the skin. This study provides, for the first time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-positive tumor cells in vivo but also normal tissues expressing the shared tumor antigen.